The fusion of antigen presenting and cancer cells leads to the formation of hybrid cells,
which are considered a potential vaccine for treating cancer. The quality assessment of …

Dendritic and tumor cells are fused to produce hybridoma cells, which are considered to be
used as cellular vaccines to treat cancer. Previous strategies for hybridoma cell production …

Background/Aim: Fusion of cancer cells has been studied for over half a century. However,
the steps involved after initial fusion between cells, such as heterokaryon formation and …

Hybrids of two different cell types are of particular interest for a couple of applications (eg
hybridoma cells for the production of monoclonal antibodies). In recent years, cancer …

Dendritic cells/tumor fusions have shown to elicit anti-cancer immunity in different cancer
types. However, the application of these vaccines for human cancer immunotherapy are …

Background Hybrids obtained by fusion between tumour cells (TC) and dendritic cells (DC)
have been proposed as anti‐tumour vaccines because of their potential to combine the …

Although the generation of hybrid cells by cell fusion plays a significant role in biotechnology
and biomedicine, the low cell‑fusion rates and the limitation of large‑scale cell fusion for …

Background: Hybrid cells generated from dendritic cells (DC) and tumour cells provide
tumour-associated antigens (TAA) in a polyvalent mode. The present study was designed to …

Hybrid cells created by fusion of antigen presenting and tumour cells have been shown to
induce potent protective and curative anti-tumour immunity in rodent cancer models. The …

Purpose The induction of potent T cell responses against tumors is the goal of tumor
immunotherapy. One approach is the fusion of antigen-presenting cells (APCs) with tumor …